GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » 10-Year ROIIC %

Celyad Oncology (XBRU:CYAD) 10-Year ROIIC % : 523.29% (As of Dec. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Celyad Oncology's 10-Year ROIIC % for the quarter that ended in Dec. 2022 was 523.29%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Celyad Oncology's 10-Year ROIIC % or its related term are showing as below:

XBRU:CYAD's 10-Year ROIIC % is ranked better than
94.7% of 1358 companies
in the Biotechnology industry
Industry Median: -35.045 vs XBRU:CYAD: 523.29

Celyad Oncology 10-Year ROIIC % Historical Data

The historical data trend for Celyad Oncology's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology 10-Year ROIIC % Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -41.41 523.29

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.41 - - 523.29 -

Competitive Comparison of Celyad Oncology's 10-Year ROIIC %

For the Biotechnology subindustry, Celyad Oncology's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's 10-Year ROIIC % falls into.



Celyad Oncology 10-Year ROIIC % Calculation

Celyad Oncology's 10-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -20.2954208 (Dec. 2022) - -9.233 (Dec. 2012) )/( 9.271 (Dec. 2022) - 11.385 (Dec. 2012) )
=-11.0624208/-2.114
=523.29%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Celyad Oncology  (XBRU:CYAD) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Celyad Oncology 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (XBRU:CYAD) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines